FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

	OMB APP	OMB APPROVAL							
SI IID	OMB Number	3235-028							

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_																
1. Name and Address of Reporting Person* Schoenberg Mark						2. Issuer Name and Ticker or Trading Symbol UroGen Pharma Ltd. [URGN]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
	ast) (First) (Middle) /O UROGEN PHARMA LTD. 99 PARK AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 09/04/2019										X Officer (give title Other (specify below) Chief Medical Officer					
(Street) NEW YO	ORK N	Y	10022		4. I	f Ame	endmei	nt, Date	e of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	•	(Zip)																		
		Tab	le I - No	n-Deriv	/ative	e Se	curit	ies Ad	quire	d, D	ispo	osed c	of, or Be	enefici	ally	Owne	d				
Date				Day/Year) Ex		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		on [4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Sec Ben Owr		ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Co	le V	- /	Amount	(A) o (D)	r Price	!	Reporte Transac (Instr. 3	tion(s)			(11150.4)	
Ordinary Shares 09/04/					4/2019	2019		N			1,041	A	(1)	6,350			D			
Ordinary Shares 09/0				09/04	4/2019	/2019		S			343(2)) D	\$33	.92	6,007			D			
		Т	able II -										or Ben ble sec			wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,		ransaction ode (Instr.				6. Date Exercisa Expiration Date (Month/Day/Yea		Amount o		of E s S ng (e Security		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	ode V		(D)	Date Exerci	sable	Exp	xpiration ate	Title	Amoun or Numbe of Shares							
Restricted Stock Units	(1)	09/04/2019			M			1,041	(3)		(3)	Ordinary Shares	1,041		\$0.00	5,209		D		

Explanation of Responses:

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ ordinary \ share \ of \ the \ Issuer.$
- 2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- 3. On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years.

Remarks:

/s/ Peter Pfreundschuh, Attorney-in-Fact 09/06/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.